Search clinical trials for: Moderate to Severe Plaque Psoriasis

Total 477748 results

Lycera Corp.

Completed

An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis

Psoriasis

United States
L.H. Kircik, M.D.

Completed

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Haus Bioceuticals

Completed

Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Psoriasis
Psoriasis Treatment Center of Central New Jersey

Unknown

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients

Psoriasis

United States
Mayne Pharma International Pty Ltd
GlaxoSmithKline

Completed

Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis

Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Innovaderm Research Inc.
Celgene

Completed

Apremilast in Palmo-Plantar Psoriasis

Palmo-plantar Psoriasis

United States, Canada
Wake Forest University Health Sciences

Completed

Biologics Anchoring Study

Moderate-to-severe Psoriasis

United States
Ferndale Laboratories, Inc.

Completed

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

Plaque Psoriasis

United States
Lotus Clinical Research, LLC
Mallinckrodt

Completed

An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.

Post Operative Pain

United States
Merck KGaA, Darmstadt, Germany

Completed

A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies

Psoriasis

United Kingdom
Postgraduate Institute of Medical Education and...

Unknown

Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis

Psoriasis Vulgaris
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)

Moderate to Severe Nail Psoriasis

Germany, Belgium, Spain, United States, Australia, United Kingdom, Denmark, Czechia, Greece
Egalet Ltd

Completed

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

Moderate-to-severe Chronic Low Back Pain

United States
GlaxoSmithKline

Completed

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States
GlaxoSmithKline

Completed

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

Purpura, Thrombocytopaenic, Idiopathic

United States, Australia, New Zealand
Novartis Pharmaceuticals

Completed

Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. (PRIME)

Psoriasis

Germany
LEO Pharma

Completed

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Jochen Schmitt.
Merck Sharp & Dohme LLC

Completed

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

Psoriasis
Cellceutix Corporation

Completed

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

Plaque Psoriasis

United States
Merck Sharp & Dohme LLC

Completed

The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)

Psoriasis
Pfizer

Completed

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Psoriasis

United States
Merck Sharp & Dohme LLC

Terminated

Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)

Psoriasis
Merck Sharp & Dohme LLC
Centocor, Inc.

Completed

A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612) (ESAQUALITY)

Psoriasis
Haus Bioceuticals

Completed

Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Psoriasis | Psoriasis Vulgaris
China Medical University Hospital

Completed

A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriasis

Taiwan
Merck KGaA, Darmstadt, Germany

Completed

CLEAR Study: Clinical Experience Acquired With Raptiva Study

Moderate to Severe Psoriasis

Switzerland
Pantec Biosolutions AG

Unknown

Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis

Psoriatic Plaque

Switzerland
AstraZeneca
Fougera Pharmaceuticals Inc.

Withdrawn

A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild to Moderate Plaque Psoriasis

Plaque Psoriasis
Merck KGaA, Darmstadt, Germany

Completed

Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis

Moderate to Severe Psoriasis

Switzerland
Pfizer

Completed

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Chronic Noncancer Pain

United States
Leon Kircik, M.D.
Stiefel, a GSK Company

Completed

Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis

Psoriasis

United States
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Tufts Medical Center
Centocor, Inc.

Completed

Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis (PPP)

Moderate to Severe Palmar Plantar Psoriasis

United States
University of California, San Francisco

Completed

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

Psoriasis

United States
Amgen

Completed

AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects

Psoriasis
Elan Pharmaceuticals

Completed

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

Stroke | Multiple Sclerosis | Muscle Spasticity | Spinal Cord Injury

United States
Merck Sharp & Dohme LLC

Completed

Photographic Library of Moderate to Severe Psoriasis Subjects Treated With Infliximab (Study P05047) (PHODYPSO)

Psoriasis
Genentech, Inc.

Completed

A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent

Psoriasis
AbbVie (prior sponsor, Abbott)

Completed

Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment (TOGETHER)

Psoriasis | Psoriatic Arthritis

Colombia
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)

Psoriasis
Narayana Medical College & Hospital

Unknown

Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.

Severe Plaque Type Psoriasis

India
AbbVie (prior sponsor, Abbott)

Terminated

Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

Moderate to Severe Psoriasis

Peru
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Promius Pharma, LLC

Completed

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

Psoriasis

United States
Boehringer Ingelheim

Completed

Double-blind, Randomised, Placebo-controlled Trial Investigating BIRT 2584 XX in Patients With Moderate/Severe Psoriasis

Psoriasis

Germany, Denmark, Belgium, Canada, France, Sweden, Netherlands, Finland, Spain, United Kingdom
Zalicus

Completed

A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis (Synergy)

Rheumatoid Arthritis

United States
Bayer
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany
Juan Ruano
Pfizer

Unknown

Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.

Metabolic Syndrome | Psoriasis Vulgaris

Spain
Toray Industries, Inc

Completed

A Pharmacokinetic Study of TRK-100STP in Japanese Patients With Renal Impairment

Renal Impairment

Japan

3

Subscribe